Stock listing

Shenzhen:002399 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (海普瑞) 股价

Home listing (Shenzhen) of Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Follow Shenzhen Hepalink Pharmaceutical Group Co., Ltd. into a list and get an email when it puts out news.

Share price · SZSE:002399

¥8.67 CNY -0.39 (-4.3%)

Close on Nov 20, 2026

Past year -28.2% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
¥8.65 – ¥8.93 CNYNov 20, 2026
Volume
3.72M sharesNov 20, 2026
Market cap
¥10.81B CNYAt the close on Nov 20, 2026 · price × 1.25B shares outstanding
52-week range
¥8.50 – ¥12.64 CNYLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
¥41.93M CNYMedian day 3.57M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
Shenzhen:002399 · Home¥8.67 CNY-0.39 (-4.3%)3,718,580¥8.92¥8.93¥8.65¥9.06Close on Nov 20, 2026
HKEX:9989$3.79 HKD-0.125 (-3.2%)958,000$3.845$3.955$3.71$3.915Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · SZSE:002399 · CNY, adjusted for splits

DayCloseChange%OpenHighLowVolume
¥8.67-0.39-4.3%¥8.92¥8.93¥8.653,718,580
¥9.06-0.02-0.2%¥9.06¥9.22¥9.011,981,676
¥9.08-0.04-0.4%¥9.02¥9.18¥9.021,782,661
¥9.12+0.02+0.2%¥9.11¥9.17¥9.031,950,236
¥9.10-0.15-1.6%¥9.26¥9.26¥9.052,832,968
¥9.250.000.0%¥9.25¥9.32¥9.172,112,520
¥9.25-0.06-0.6%¥9.29¥9.36¥9.202,011,020
¥9.31-0.01-0.1%¥9.42¥9.42¥9.302,304,540
¥9.32-0.12-1.3%¥9.50¥9.51¥9.312,856,018
¥9.44-0.16-1.7%¥9.43¥9.58¥9.382,651,353
¥9.60+0.17+1.8%¥9.40¥9.62¥9.383,708,854
¥9.43+0.12+1.3%¥9.37¥9.45¥9.174,291,900
¥9.31-0.01-0.1%¥9.24¥9.42¥9.213,070,200
¥9.32+0.10+1.1%¥9.22¥9.35¥9.103,862,100
¥9.22+0.14+1.5%¥9.27¥9.43¥8.975,365,973
¥9.08-0.13-1.4%¥9.18¥9.24¥9.072,004,000
¥9.21+0.15+1.7%¥9.06¥9.30¥9.053,028,400
¥9.06-0.29-3.1%¥9.39¥9.42¥9.062,845,800
¥9.35+0.08+0.9%¥9.20¥9.42¥9.183,079,900
¥9.27+0.13+1.4%¥9.11¥9.27¥8.953,102,200
¥9.14-0.19-2.0%¥9.33¥9.36¥9.142,519,200
¥9.33-0.07-0.7%¥9.41¥9.49¥9.311,950,500
¥9.40+0.07+0.8%¥9.31¥9.41¥9.282,064,860
¥9.33+0.01+0.1%¥9.30¥9.45¥9.232,245,400
¥9.32-0.08-0.9%¥9.49¥9.66¥9.233,601,520
¥9.40-0.07-0.7%¥9.35¥9.49¥9.312,592,000
¥9.47-0.15-1.6%¥9.59¥9.61¥9.453,096,540
¥9.62-0.11-1.1%¥9.65¥9.68¥9.454,053,160
¥9.73-0.16-1.6%¥9.88¥9.94¥9.693,749,140
¥9.89+0.14+1.4%¥9.72¥9.90¥9.583,759,000
¥9.75-0.10-1.0%¥9.99¥10.00¥9.704,326,820
¥9.85+0.24+2.5%¥9.61¥9.92¥9.564,148,623
¥9.61-0.05-0.5%¥9.65¥9.77¥9.562,899,500
¥9.66+0.08+0.8%¥9.63¥9.70¥9.573,231,383
¥9.58-0.15-1.5%¥9.73¥9.80¥9.503,541,620
¥9.73-0.02-0.2%¥9.73¥9.88¥9.713,278,200
¥9.75-0.05-0.5%¥9.79¥9.86¥9.633,896,500
¥9.80+0.45+4.8%¥9.37¥9.81¥9.376,347,909
¥9.35-0.13-1.4%¥9.48¥9.69¥9.356,234,608
¥9.48+0.06+0.6%¥9.43¥9.50¥9.391,862,900
¥9.42+0.04+0.4%¥9.40¥9.43¥9.292,438,280
¥9.38-0.23-2.4%¥9.61¥9.63¥9.382,121,000
¥9.61+0.13+1.4%¥9.47¥9.65¥9.442,512,524
¥9.48-0.34-3.5%¥9.75¥9.81¥9.404,419,170
¥9.82-0.17-1.7%¥9.94¥9.95¥9.803,893,700
¥9.99-0.04-0.4%¥9.98¥10.02¥9.903,358,500
¥10.03+0.19+1.9%¥9.84¥10.04¥9.794,734,148
¥9.84+0.01+0.1%¥9.79¥9.86¥9.744,028,348
¥9.83-0.06-0.6%¥9.92¥9.99¥9.814,175,920
¥9.89-0.08-0.8%¥9.98¥10.09¥9.894,148,042
¥9.97-0.11-1.1%¥9.96¥10.08¥9.914,488,328
¥10.08+0.04+0.4%¥10.01¥10.16¥9.975,827,285
¥10.04-0.41-3.9%¥10.18¥10.22¥9.957,688,460
¥10.45-0.15-1.4%¥10.51¥10.59¥10.425,347,000
¥10.60+0.20+1.9%¥10.38¥10.60¥10.316,685,978
¥10.40+0.09+0.9%¥10.33¥10.78¥10.338,545,934
¥10.31+0.31+3.1%¥10.03¥10.39¥9.919,611,128
¥10.00-0.47-4.5%¥10.40¥10.46¥9.9812,512,234
¥10.47-0.81-7.2%¥11.51¥11.57¥10.4522,933,199
¥11.28+1.03+10.0%¥11.02¥11.28¥11.028,784,664

Splits

2 splits since 2011 · SZSE:002399 · every price before a split is adjusted for it

DayRatioWhat
8-for-5Split
2-for-1Split
Ticker
Shenzhen:002399
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
Shenzhen
Currency
CNY

Latest news

All Shenzhen Hepalink Pharmaceutical Group Co., Ltd. news

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
11 in all · newest May 6, 2021 · oldest 2020

Where Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is listed

ListingExchangeCountryCurrency
Shenzhen:002399 海普瑞 · Home listing · This pageShenzhenChinaCNY
HKEX:9989 海普瑞HKEXHong KongHKD

Valuation

P/E 57.0× against a median of 13.6×: 7th lowest of 9 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
¥6.57B CNY
P/E
57.0×
EV/sales
1.3×
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
0.9×
Gross margin
34.0%
Operating margin
11.6%
Net margin
3.7%
Debt to equity
0.0×
Beta
No index for this market yet

Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class A · SZSE:002399US$1.62BUS$986.2M57.0×1.3×n/a0.9×3.7%0.0×n/a
Ultragenyx Pharmaceutical Inc. · NASDAQ:RAREUS$1.68BUS$2.60Bn/a3.6×n/an/a−71.8%n/a1.35
Supernus Pharmaceuticals, Inc. · NASDAQ:SUPNUS$1.67BUS$1.85B3.7×1.4×n/an/a32.9%n/a0.67
Caplin Point Laboratories Limited · NSE:CAPLIPOINTUS$1.66BUS$1.56B23.2×6.3×18.1×4.3×29.1%0.0×n/a
AstraZeneca Pharma India Limited · NSE:ASTRAZENUS$1.66BUS$1.60B86.8×5.7×59.3×17.5×6.8%0.0×n/a
Hugel, Inc. · KRX:145020US$1.66BUS$1.21B14.1×3.4×7.1×2.1×32.9%0.0×n/a
Agios Pharmaceuticals, Inc. · NASDAQ:AGIOUS$1.65BUS$1.05Bn/a7.4×n/a1.7×−264.8%0.0×1.10
Faes Farma, S.A. · BME:FAEUS$1.65BUS$1.93B11.0×1.7×5.8×1.9×13.1%0.5×n/a
Consun Pharmaceutical Group Ltd. · HKEX:1681US$1.64BUS$1.06B10.1×2.1×5.6×2.3×31.6%0.1×n/a
BrightGene Bio-Medical Technology Co. Ltd. Class A · SSE:688166US$1.63BUS$1.68B106×8.3×n/a3.5×7.6%0.5×n/a
NATCO Pharma Limited · NSE:NATCOPHARMUS$1.62BUS$1.62B13.1×4.3×14.2×1.6×32.8%0.0×n/a
Median of the othersUS$1.65BUS$1.61B13.6×3.9×10.7×2.2×21.1%0.0×1.10

Forecasts

Analysts' consensus from EODHD, read Nov 9, 2026. Not 6ix's view and not investment advice.

Price target
7.50 CNY · Analysts' mean
EPS, year to Dec 2026
0.50 · 1 analyst
Revenue, year to Dec 2026
5.1B · 1 analyst

Team and board

Officers

OfficerRole
Juan ChenChief Financial Officer
Li LiPresident and Chairman
Fengqi QianSecretary to the Board, Joint Company Secretary
Tan LiExecutive Director, Deputy General Manager
Yu ShanExecutive Director, General Manager

Board

DirectorRole
Li LiPresident and Chairman
Fengqi QianSecretary to the Board, Joint Company Secretary
Tan LiExecutive Director, Deputy General Manager
Yu ShanExecutive Director, General Manager

Events

QuarterResultsShare move
Q3 2026Oct 30, 2026+2.6%
Q2 2026Aug 31, 2026−3.5%
Q1 2026Apr 30, 2026
Q4 2025Mar 30, 2026+2.0%
Q3 2025Oct 31, 2025+4.7%
Q2 2025Sep 1, 20250.0%
Q1 2025Apr 25, 2025−2.7%
Q3 2024Oct 30, 2024 · Before open−0.7%
Q2 2024Sep 2, 2024+0.7%
Q1 2024Apr 29, 2024 · Before open+2.2%
All 20 quarters
QuarterResultsShare move
Q4 2023Jan 10, 2024 · After close+1.0%
Q3 2023Oct 30, 2023 · Before open+2.0%
Q2 2023Aug 30, 2023 · After close+1.1%
Q1 2023Apr 28, 2023 · Before open+0.1%
Q4 2022Mar 29, 2023 · After close−0.1%
Q3 2022Oct 28, 2022 · After close−6.0%
Q2 2022Aug 29, 2022 · Before open+5.4%
Q1 2022Apr 29, 2022 · After close
Q4 2021Mar 30, 2022 · Before open+2.0%
Quarter to Sep 30, 2021Oct 27, 2021 · Before open−1.9%

Open Events

Financials

Annual, in CNY

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue5.48B5.26B5.43B7.16B6.37B5.33B4.62B4.81B2.84B2.26B
Cost of revenue3.74B3.52B4.49B4.86B4.37B3.30B2.95B2.93B1.98B1.56B
Gross profit1.74B1.74B940.9M2.30B2.00B2.03B1.68B1.88B862.9M697.5M
Research and development226.2M212.0M182.4M252.1M221.1M160.0M148.7M186.5M93.5M62.0M
Selling, general and administrative478.2M638.5M674.5M457.2M420.2M412.7M352.9M295.1M382.3M389.6M
Operating income636.0M507.1M-434.2M828.6M227.5M1.33B1.31B692.5M92.2M435.6M
Depreciation and amortization372.9M331.1M373.6M307.7M302.7M304.0M255.6M217.0M155.2M161.8M
EBITDA1.01B838.2M-60.6M1.14B530.2M1.63B1.57B909.5M247.4M597.4M
Interest expense71.4M153.5M238.7M257.2M201.6M273.6M278.3M227.5M184.5M106.7M
Income before tax402.2M726.2M-928.3M829.9M222.3M1.33B1.31B702.2M104.2M474.9M
Income tax101.3M-126.2M114.8M-11.1M306.2M271.4M134.0M-94.8M88.8M
Net income349.5M646.7M-783.3M727.4M240.8M1.02B1.06B591.5M196.7M396.9M
Earnings per share, basic0.240.44-0.530.500.160.760.850.470.160.32

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents1.35B1.69B1.85B2.14B2.94B2.71B1.28B2.12B3.50B4.55B
Short-term investments1.48B868.4M414.2M1.31B981.2M828.2M112.6M79.2M288.4M13.4M
Receivables1.37B1.28B1.26B1.63B1.54B1.88B1.32B1.09B1.03B719.4M
Inventory4.45B5.39B6.65B6.84B4.71B3.17B2.37B1.53B857.3M584.8M
Current assets9.15B9.62B10.6B12.4B10.8B9.13B6.00B5.60B6.13B6.70B
Property, plant and equipment2.54B2.57B2.58B2.44B1.88B1.22B
Goodwill2.30B2.36B2.32B2.35B2.15B2.20B2.35B2.32B2.21B2.34B
Total assets16.6B17.3B19.2B20.8B19.1B19.0B15.2B13.7B13.2B12.9B
Accounts payable257.1M299.7M302.2M427.4M385.8M239.2M228.7M205.3M164.3M70.9M
Current liabilities3.95B3.70B4.99B5.58B4.79B3.61B4.97B4.50B3.25B2.07B
Long-term debt298.1M1.08B1.81B2.30B2.25B3.09B2.36B2.46B1.83B2.10B
Total debt2.98B5.56B6.46B5.65B5.65B6.30B4.92B4.71B3.89B
Total liabilities4.55B5.14B7.22B8.41B7.58B7.34B7.77B7.41B5.50B4.83B
Shareholders' equity12.0B12.1B11.9B12.3B11.4B11.6B7.35B6.07B7.58B7.97B
Shares outstanding1.47B1.47B1.48B1.47B1.47B1.35B1.25B1.25B1.25B1.25B

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations1.71B2.19B398.2M-756.6M-6.63M37.3M-227.6M667.9M-407.1M346.1M
Capital spending-121.1M-202.8M-444.9M-222.4M-193.9M-212.5M-362.1M-535.0M-576.1M-359.5M
Free cash flow1.59B1.99B-46.7M-979.0M-200.5M-175.2M-589.7M132.9M-983.2M-13.5M
Cash from investing-415.0M1.22B249.8M719.9M-2.17B1.70M-544.3M-1.21B-273.0M
Cash from financing-2.14B-1.20B329.6M-501.1M2.51B-234.3M-1.62B564.5M274.2M
Dividends paid-430.8M-159.9M-425.9M-51.4M-220.1M-224.5M-342.5M-255.1M-444.6M-541.4M
Share buybacks-473.0M
Change in cash-233.3M-343.8M445.9M-159.9M149.4M253.7M-449.6M-1.47B-1.06B360.3M

Open Financials

Cap table

Built by 6ix from Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class A’s releases

Common shares
1,247,201,704
Fully diluted
1,247,201,704

Fully diluted

LineShares
Common shares1,247,201,704

Share count over time

CountShares
Nov 22, 20261,247,201,704

Open Cap table

Shareholders

HolderSharesValueAs of
Vanguard Total International Stock Index Fund735KUS$1.06MJul 31, 2026
Vanguard Emerging Markets Stock Index Fund706KUS$1.01MJul 31, 2026
State Street(R) SPDR(R) Portfolio Emerging Markets ETF341KUS$451KJun 30, 2026
Emerging Markets Core Equity 2 Portfolio286KUS$411KJul 31, 2026
Vanguard Ftse All-World Ex-Us Index Fund112KUS$161KJul 31, 2026
Dimensional Emerging Markets Core Equity 2 ETF86,013US$123KJul 31, 2026
The Emerging Markets Small Cap Series74,545US$107KJul 31, 2026
Dimensional Emerging Core Equity Market ETF58,871US$84,447Jul 31, 2026
State Street(R) SPDR(R) S&P(R) China ETF58,396US$77,253Jun 30, 2026
Dimensional World ex. U.S. Core Equity 2 ETF36,126US$51,820Jul 31, 2026
All 21 holders
HolderSharesValueAs of
Vanguard Total World Stock Index Fund35,925US$51,535Jul 31, 2026
Emerging Markets Social Core Equity Portfolio32,494US$46,613Jul 31, 2026
Dimensional Emerging Markets Value ETF28,862US$41,401Jul 31, 2026
World ex U.S. Core Equity Portfolio26,377US$37,839Jul 31, 2026
Emerging Markets Sustainability Core 1 Portfolio15,865US$22,758Jul 31, 2026
World ex U.S. Targeted Value Portfolio8,984US$12,887Jul 31, 2026
Emerging Markets Targeted Value Portfolio8,792US$12,613Jul 31, 2026
Vanguard ESG International Stock ETF8,200US$12,043May 31, 2026
Xtrackers Emerging Markets Carbon Reduction and Climate Improvers ETF6,488US$9,104May 29, 2026
Goldman Sachs MarketBeta Total International Equity ETF794US$1,167May 29, 2026
Goldman Sachs MarketBeta Emerging Markets Equity ETF452US$664May 31, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Fengqi QianSecretary to the Board, Joint Company Secretary · Since at least Nov 6, 2026
Juan ChenChief Financial Officer · Since at least Nov 6, 2026
Li LiPresident and Chairman · Since at least Nov 6, 2026
Tan LiExecutive Director, Deputy General Manager · Since at least Nov 6, 2026
Yu ShanExecutive Director, General Manager · Since at least Nov 6, 2026

Open People

Log in to ask 6ix AI your own questions about Shenzhen Hepalink Pharmaceutical Group Co., Ltd.